Keyphrases
Leukemia
100%
Braking
100%
Arginine
100%
Metabolic
100%
T Cells
75%
Azacitidine
50%
Vorinostat
50%
Acute Myeloid Leukemia
25%
Cytotoxicity
25%
Preclinical Data
25%
Microenvironment
25%
Immune Response
25%
Antigen-specific T Cells
25%
Phase II Trial
25%
Chimeric Antigen Receptor T Cells (CAR-T)
25%
Therapeutic Approaches
25%
Antigen Stimulation
25%
Circulating Antigen
25%
CD33
25%
T Cell Exhaustion
25%
Copyright
25%
Programmed Death-ligand 1 (PD-L1)
25%
Cancer-testis Antigen
25%
Arginine Metabolism
25%
T Cell Cytotoxicity
25%
Therapeutic Targeting
25%
Arginase Activity
25%
Arginase 2
25%
SSX2
25%
Medicine and Dentistry
T Cell
100%
Leukemia
100%
Immunotherapy
100%
Arginine
100%
Acute Myelogenous Leukemia
80%
Cytotoxicity
40%
Vorinostat
40%
Arginase
40%
Azacitidine
40%
Acute Myeloid Leukemia
20%
Immune Response
20%
Upregulation
20%
Antigen Specificity
20%
Phase II Trials
20%
Cancer Testis Antigen
20%
Immunostimulation
20%
Chimeric Antigen Receptor T-Cell
20%
Immunology and Microbiology
T Cell
100%
Immunotherapy
100%
Arginine
100%
Cytotoxicity
40%
Immune Response
20%
Blood Plasma
20%
Upregulation
20%
Myeloid
20%
Antigen Specificity
20%
Immunostimulation
20%
CD33
20%
Cancer Testis Antigen
20%
Chimeric Antigen Receptor T-Cell
20%